Peptide-Based Hydrogel Nanoparticles for Biocompatible Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methodologies for preparing nanoparticles for drug delivery often involve complex synthetic techniques and chemicals that compromise biocompatibility, making them unsuitable for effective and safe use in biomedical applications.
Innovation Solution
The development of peptide-based hydrogel nanoparticles (HNPs) formed through self-assembly of aromatic dipeptides, such as Fmoc-FF, using a scalable process that avoids hazardous chemicals and allows for controlled release of bioactive agents, enabling targeted drug delivery and diagnostic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymer-based nanoparticles (PLGA, liposomes) are used for drug delivery, then encapsulation efficiency and controlled release are achieved, but biocompatibility is compromised due to complex synthetic techniques and hazardous chemicals
Solution Approach 1:
The patent changes the fundamental material parameter from synthetic polymers to self-assembling peptides (e.g., Fmoc-FF, Fmoc-Phe-Phe), which naturally form hydrogel nanoparticles through non-covalent interactions. This parameter change eliminates the need for complex chemical synthesis while maintaining nanoparticle formation capability, thereby improving biocompatibility without sacrificing manufacturability
Solution Approach 2:
The invention utilizes the self-assembling property of aromatic dipeptides that automatically organize into hydrogel nanoparticles through hydrophobic interactions and hydrogen bonding. This self-service mechanism eliminates the need for complex external synthesis procedures, hazardous chemicals, and extreme processing conditions, directly resolving the contradiction between biocompatibility and manufacturing simplicity
2Stability of the object's composition
If synthetic polymers are used to form hydrogel nanoparticles, then nanoparticle formation is achieved, but biocompatibility deteriorates due to use of extreme temperatures, pHs, and hazardous chemicals
Solution Approach 1:
The patent converts the typically harmful hydrophobic interactions that cause protein aggregation into a beneficial self-assembly mechanism. Aromatic dipeptides with hydrophobic side chains (e.g., phenylalanine) naturally aggregate through these interactions to form stable hydrogel nanoparticles, transforming what would normally be a harmful effect into the driving force for nanoparticle formation, thereby achieving stable structure without compromising biocompatibility
3Quantity of substance
If complex multi-step synthetic pathways are used for nanoparticle preparation, then encapsulation efficiency is improved, but manufacturing complexity increases
Solution Approach 1:
The patent incorporates the bioactive agent into the nanoparticle structure during the self-assembly process itself, rather than requiring separate encapsulation steps. The peptide nanocarriers are formed in the presence of the therapeutic agent, allowing simultaneous nanoparticle formation and drug incorporation in a single step, thereby achieving high encapsulation efficiency without multi-step synthesis
Solution Approach 2:
The invention merges the nanoparticle formation process with the drug encapsulation process into a single unified operation. The self-assembling peptides and therapeutic agent co-assemble together in one step, combining what would traditionally be separate processes (nanoparticle synthesis and drug loading) into a single streamlined operation, reducing manufacturing complexity while maintaining encapsulation efficiency
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide-based HNPs provide a biocompatible and efficient platform for delivering hydrophilic and hydrophobic bioactive substances, offering controlled release and improved bioavailability, while being easy to manufacture and modify for enhanced targeting and stability.
Implementation Method 1
aromatic dipeptides such as N-fluorenylmethoxycarbonyl-diphenylalanine (Fmoc-FF), self-assemble in aqueous solutions to form nano-scale ordered hydrogels
Implementation Method 2
aromatic dipeptides... self-assemble in aqueous solutions to form nano-scale ordered hydrogels of remarkable mechanical rigidity
Data Source
AI summary
Compositions comprising self-assembled hydrogel particles formed of short peptides which comprise one or more aromatic amino acid residue(s) in an inverted emulsion are disclosed. Such hydrogel particles which encapsulate an active agent and uses thereof in therapeutic and diagnostic applications are also disclosed.